RSS feeds allow Web site content to be gathered via feed reader software. Click the subscribe link to obtain the feed URL for this page. The feed will update when new content appears on this page.

GlaxoSmithKline PLC

A collection of news and information related to GlaxoSmithKline PLC published by this site and its partners.

Top GlaxoSmithKline PLC Articles

Displaying items 13-24
  • Wealthy nations must follow through on disease fight

    Wealthy nations must follow through on disease fight
    In 1980, I moved my family from Maryland to the White Mountain Apache Reservation in Arizona to work on an issue most people are not comfortable talking about — diarrhea. At the time, diarrhea, which is preventable and treatable, was rampantly...
  • Ripley's opens Odditorium at Harborplace

    Ripley's Believe It or Not, one of the first of several new tenants opening for the summer tourist season at Harborplace in downtown Baltimore, will open Saturday in the Light Street Pavilion. Ripley Entertainment Inc. said exhibits at the Inner Harbor...
  • Hands-on science program at Laurel Museum

    The Laurel Historical Society is one of five community sites selected to offer free science education classes for second- to sixth-graders through GlaxoSmithKline's Science in the Summer program. Classes will be held Aug. 6 to 9 at the Laurel Museum, 817...
  • GlaxoSmithKline to acquire Human Genome Sciences

    GlaxoSmithKline to acquire Human Genome Sciences
    After spurning a hostile takeover bid from GlaxoSmithKline PLC in April, Human Genome Sciences Inc. said Monday it agreed to be bought by the biopharmaceutical giant for a more lucrative offer valued at $3.6 billion. GlaxoSmithKline boosted its offer for...
  • Human Genome Sciences rebuffs $2.6 billion offer from GlaxoSmithKline

    Shares of Human Genome Sciences doubled in Thursday morning trading on news that a major British biopharmaceutical company offered to buy it for $2.6 billion, which the Rockville company rejected as too low. Human Genome, which uses the human DNA...
  • FDA approves new drug for erectile dysfunction

    Men now have a new option to treat erectile dysfunction. The U.S. Food and Drug Administration has approved the new drug Stendra to treat the illness that causes problems in the sex lives of 30 million men. It is the first erectile dysfunction drug in a...
  • Medicamento contra el ébola ZMapp cura a todos los monos de un estudio

    NUEVA YORK (Reuters) - El medicamento experimental contra el ébola ZMapp curó a los 18 monos de laboratorio infectados con el letal virus, entre ellos incluso aquellos que sufrieron la fibre y hemorragias características de la enfermedad y sólo a horas de...
  • Ebola vaccine to be tested on human volunteers, starting in September

     Ebola vaccine to be tested on human volunteers, starting in September
    GlaxoSmithKline announced Thursday, Aug. 28, that it will begin testing its Ebola vaccination as early as mid-September in human volunteers    With the help of the National Institutes of Health’s Vaccine Research Center, GSK will start...
  • BioCryst expects to begin Ebola study in weeks

    (Reuters) - BioCryst Pharmaceuticals Inc said it expects to initiate a study within weeks to test its antiviral in primates for use against Ebola infections The biotechnology company's stock was up about 5.4 percent in premarket trading after it also...
  • Wanted: 60 volunteers to test Ebola vaccine in middle England

    LONDON (Reuters) - Fancy testing an Ebola vaccine? It may sound scary but the scientist behind the British trial of a shot that has so far only been given to monkeys sees little risk and is optimistic he will drum up enough volunteers. Adrian Hill,...
  • Gene studies of Ebola in Sierra Leone show virus is mutating fast

    CHICAGO (Reuters) - Genetic studies of some of the earliest Ebola cases in Sierra Leone reveal more than 300 genetic changes in the virus as it leapt from person to person, changes that could blunt the effectiveness of diagnostic tests and experimental...
  • Vacuna de GSK para el ébola entra en vía rápida para pruebas clínicas

    LONDRES/NUEVA YORK (Reuters) - Una vacuna experimental para el ébola de GlaxoSmithKline será llevada rápidamente a estudios en humanos y la compañía planea elaborar existencias de hasta 10.000 dosis para un despliegue de emergencia si los resultados son...